Osteogenesis Imperfecta Treatment Market, by Drugs (Teriparatide, and Denosumab), By Treatment Type (Medication, Physical Therapy, Surgery), By Route of Administration (Oral, Intravenous, Subcutaneous), By End Use (Hospital, Home Care, Specialty Clinics), and By Geography (EU, NA, APAC, LATAM, and MEA) Analysis, Size, Share, Trends, & Forecast from 2021-2027
REPORT HIGHLIGHT
The global Osteogenesis Imperfecta Treatment market was valued at USD 662.6 Million in 2019, growing with 1.8% CAGR during the forecast period, 2021-2027.
Osteogenesis imperfecta is genetic bone disorders characterized by bone fractures and deformities. It is also known as brittle bone disease. It is caused by a genetic mutation that affects the body’s production of collagen and structure in the human body. Collagen is the major protein component of the extracellular matrix in the bone, tendon, and skin, and therefore, it is very important for the proper structure and strength of bones. The mutant collagen alters bone formation and results in bone deformity.
Market Dynamics
Key factors that drive the growth of the osteogenesis imperfecta treatment market are advanced market intelligence, drug designation approvals, and strategic researches, and licensing agreement between companies that are expected to raise the market growth while synthesizing abundant growth opportunities in the market during the forecast period. The market is slightly driven by the research & development activities to develop novel therapies for the treatment of osteogenesis imperfecta and also to create advanced drugs for the patients suffering from this disorder.
However, a permanent treatment is still unavailable due to low awareness about osteogenesis imperfecta which acts as a market restraining factor. In addition, a lack of trained professionals in a few developing countries further creates low popularity scenarios for such disorders in the healthcare sector.
Drugs Takeaway
Based on drugs, the market is segmented into Teriparatide, Denosumab, and Others. The market for Denosumab is expected to grow at a higher CAGR of 2.5% during the forecast period. Teriparatide drugs are expected to acquire a larger share in the market due to their effectiveness in the treatment procedure, affordable pricing, and other benefits.
Treatment Type Takeaway
Based on treatment type, the osteogenesis imperfecta treatment market is segmented into medication, surgery, physical therapy, and other treatment types such as stem-cell therapy. The market for other therapies such as stem-cell therapy is expected to grow at a higher CAGR of more than 3% during the forecast period. This procedure involves stem cell transplant into the osteogenesis imperfecta baby during pregnancy or soon after birth. These stem cells are expected to make healthy collagen in the baby’s body that might support damaged bones and help with the development of new normal bone.
Routes of Administration Takeaway
Based on routes and administration, the worldwide market is segmented into oral, intravenous, subcutaneous and others. The market for Intravenous routes is expected to grow at a higher CAGR of 3.1% during the forecast period. Intravenous bisphosphonate therapy is broadly used to treat bone fragility in children with osteogenesis imperfecta.
End-use Takeaway
Based on end-users, the industry is segmented into hospitals, home care, specialty clinics, and others. The market for hospital-acquired the largest share in 2019, mainly due to more patient traffic and better infrastructure for treatment. The market for specialty clinics is expected to grow at a higher CAGR of 3.3% during the forecast period. Specialty clinics are now presenting precise treatment infrastructure and are gaining much popularity due to specific treatment facilities.
Regional Takeaway
At regional levels, the overall industry is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. The European region is expected to occupy maximum market share, mainly due to the presence of various medical equipment and drugs, technological and research and development infrastructure, and capital investments in the region’s healthcare landscape. Europe accounted for a total share of 37.5% in 2019 due to increasing R&D investments and frequent clinical trials in the region and the availability of state-of-the-art research facilities to increase the sector‘s growth. The U.K. is expected to be the chief revenue generating country in the North American region.
On the other hand, the Asia-Pacific region is one of the fast-growing with the highest CAGR of 4.6% during the forecast period. The region’s high-growth is mainly due to an untapped market and ongoing initiatives undertaken by key players and orphan drug designations for the treatment of this disorder.
COVID-19 Impact
Our research suggests that the impacts of COVID-19 on the osteogenesis imperfecta treatment industry will be towards the investment policies of the key players. Due to the global economic slowdowns, many medium and small-range companies are hesitating to invest and expand on the research and development fronts. However, large firms are expected to capitalize on this opportunity and will keep an eye on acquiring of smaller firms that are dwindling in this recession. On the same hand, the government and other public organizations are expected to aid healthcare institutes in facilitating the concerned infrastructure in order to facilitate funding and other requirements for further research in the medical and treatment field.
Key Vendor Takeaway
The leading players include Celgene, Bone Therapeutics, Mereo BioPharma Group, Jubilant Life Sciences, Eli Lilly and Company, Aurobindo Pharma, Genzyme Corporation, Teva Pharmaceutical, Merck & Co, Cipla Inc., Mylan N.V., Sun Pharmaceutical, and Amgen Inc., among others. Companies are actively involved in investing in a number of clinical trials during the review period. A collaborative research process among the research institutes and suppliers of drugs for OI treatment and other regulatory authorities is expected to bolster the osteogenesis imperfecta treatment market growth during the forecast period.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2016 to 2018
- Base Year – 2019
- Estimated Year – 2020
- Projected Year – 2021 to 2027
TARGET AUDIENCE
- Healthcare institutes
- Medical instruments and drugs distributors, and suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL OSTEOGENESIS IMPERFECTA TREATMENT MARKET KEY PLAYERS
- Celgene Corporation
- Cipla Inc.
- Bone Therapeutics
- Jubilant Life Sciences Ltd.
- Mereo BioPharma Group
- Aurobindo Pharma
- Teva Pharmaceutical Industries
- Genzyme Corp.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Limited
- Mylan N.V.
- Amgen Inc.
GLOBAL OSTEOGENESIS IMPERFECTA TREATMENT MARKET, BY DRUGS
- Teriparatide
- Denosumab
- Others
GLOBAL OSTEOGENESIS IMPERFECTA TREATMENT MARKET, BY TREATMENT TYPE
- Medication
- Surgery
- Physical Therapy
- Others
GLOBAL OSTEOGENESIS IMPERFECTA TREATMENT MARKET, BY ROUTES OF ADMINISTRATION
- Oral
- Intravenous
- Subcutaneous
- Others
GLOBAL OSTEOGENESIS IMPERFECTA TREATMENT MARKET, BY END USE
- Hospital
- Home care
- Specialty clinics
- Others
GLOBAL OSTEOGENESIS IMPERFECTA TREATMENT MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Singapore
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. OSTEOGENESIS IMPERFECTA TREATMENT MARKET OVERVIEW
1.1. Study Scope
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Drugs
2.1.2. Market Snippet by Treatment Type
2.1.3. Market Snippet by Routes of administration
2.1.4. Market Snippet by End use
2.1.5. Market Snippet by Region
2.2. Competitive Insights
3. OSTEOGENESIS IMPERFECTA TREATMENT KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. OSTEOGENESIS IMPERFECTA TREATMENT INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. OSTEOGENESIS IMPERFECTA TREATMENT MARKET: COVID-19 IMPACT ANALYSIS
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Loser Segments
5.2.4. Marginal Loss Segments
6. OSTEOGENESIS IMPERFECTA TREATMENT MARKET LANDSCAPE
6.1. Market Share Analysis, 2019
6.2. Key Innovators Analysis
6.3. Breakdown Data, by Key Manufacturer
6.3.1. Established Players’ Analysis
6.3.2. Emerging Players’ Analysis
7. OSTEOGENESIS IMPERFECTA TREATMENT MARKET – BY DRUGS
7.1. Overview
7.1.1. Segment Share Analysis, By Drugs, 2020 & 2027 (%)
7.2. Teriparatide7.2.1. Overview7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.3. Denosumab
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.4. Other drugs
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8. OSTEOGENESIS IMPERFECTA TREATMENT MARKET – BY TREATMENT TYPE
8.1. Overview
8.1.1. Segment Share Analysis, By Drugs, 2020 & 2027 (%)
8.2. Medication
8.2.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.3. Physical therapy
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.4. Surgery
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.5. Others
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.5.3. 9. OSTEOGENESIS IMPERFECTA TREATMENT MARKET – BY ROUTES OF ADMINISTRATION
9.1. Overview
9.1.1. Segment Share Analysis, By Drugs, 2020 & 2027 (%)
9.2. Oral
9.2.1. Overview
9.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3. Intravenous
9.3.1. Overview
9.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.4. Subcutaneous
9.4.1. Overview
9.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.5. Others
9.5.1. Overview
9.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10. OSTEOGENESIS IMPERFECTA TREATMENT MARKET – BY END USE
10.1. Overview
10.1.1. Segment Share Analysis, By Organization, 2020 & 2027 (%)
10.2. Hospitals
10.2.1. Overview
10.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3. Homecare
10.3.1. Overview
10.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.4. Specialty Clinics
10.4.1. Overview
10.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.5. Others
10.5.1. Overview
10.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11. OSTEOGENESIS IMPERFECTA TREATMENT MARKET– BY GEOGRAPHY
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
11.2. North America
11.2.1. Overview
11.2.2. Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
11.2.4. North America Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.2.5. North America Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.2.7. North America Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.3.9. Italy
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.3.9.3. Italy Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.3.9.4. Italy Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.3.9.6. Italy Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.3.10. United Kingdom
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.3.10.3. United Kingdom Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.3.10.4. United Kingdom Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.3.10.6. United Kingdom Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.3.11. France
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.3.11.3. France Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.3.11.4. France Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.3.11.5. France Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.3.11.6. France Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.3.12. Rest of Europe
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.3.12.3. Rest of the Europe Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.3.12.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.3.12.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.3.12.6. Rest of the Europe Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Key Manufacturers in Asia Pacific
11.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
11.4.4. Asia Pacific Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.4.7. Asia Pacific Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.4.8. India
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.4.8.3. India Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.4.8.4. India Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.4.8.5. India Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.4.8.6. India Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.4.9. China
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.4.9.3. China Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.4.9.4. China Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.4.9.5. China Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.4.9.6. China Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End use, 2016 – 2027 (US$)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.4.12. Rest of APAC
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.4.12.3. Rest of APAC Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.4.12.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.4.12.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.4.12.6. Rest of APAC Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.5. Latin America
11.5.1. Overview
11.5.2. Key Manufacturers in Latin America
11.5.3. Latin America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
11.5.4. Latin America Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.5.5. Latin America Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.5.7. Latin America Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.5.11. Rest of LATAM
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.5.11.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.5.11.6. Rest of LATAM Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.6. Middle East and Africa
11.6.1. Overview
11.6.2. Key Manufacturers in Middle East and Africa
11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
11.6.4. Middle East and Africa Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.6.7. Middle East and Africa Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Drugs, 2016 – 2027 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2016 – 2027 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End use, 2016 – 2027 (US$ Million)
12. KEY VENDOR ANALYSIS
12.1. Competitive Dashboard
12.2. Company Profiles
12.2.1. Cipla Inc.
12.2.1.1. Company Snapshot
12.2.1.2. Financial Performance
12.2.1.3. Product Benchmarking
12.2.1.4. Strategic Initiatives
12.2.2. Celgene Corporation
12.2.3. Bone Therapeutics
12.2.4. Jubilant Life Sciences
12.2.5. Mereo BioPharma Group
12.2.6. Aurobindo Pharma
12.2.7. Mylan N.V.
12.2.8. Sun Pharmaceutical Industries
12.2.9. Genzyme Corp12.2.10. Amgen Inc.
13. 360 DEGREE ANALYSTVIEW
14. APPENDIX
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
List of Tables
TABLE List of data Drugss
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Osteogenesis Imperfecta Treatment market: Drugss Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope
TABLE Global Osteogenesis Imperfecta Treatment market, by Organization 2016-2027 (USD Million)
TABLE Osteogenesis Imperfecta Treatment market: Organization Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by End use
TABLE Global Osteogenesis Imperfecta Treatment market, by End use 2016-2027 (USD Million)
TABLE Osteogenesis Imperfecta Treatment market: Regional snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global Osteogenesis Imperfecta Treatment market, by Region 2016-2027 (USD Million)
TABLE North America Osteogenesis Imperfecta Treatment market, by Country, 2016-2027 (USD Million)
TABLE North America Osteogenesis Imperfecta Treatment market, by Drugs, 2016-2027 (USD Million)
TABLE North America Osteogenesis Imperfecta Treatment market, by treatment type, 2016-2027 (USD Million)
TABLE North America Osteogenesis Imperfecta Treatment market, by route of administration, 2016-2027 (USD Million)
TABLE North America Osteogenesis Imperfecta Treatment market, by End use, 2016-2027 (USD Million)
TABLE Europe Osteogenesis Imperfecta Treatment market, by Country, 2016-2027 (USD Million)
TABLE Europe Osteogenesis Imperfecta Treatment market, by Drugs, 2016-2027 (USD Million)
TABLE Europe Osteogenesis Imperfecta Treatment market, by treatment type, 2016-2027 (USD Million)
TABLE Europe Osteogenesis Imperfecta Treatment market, by route of administration, 2016-2027 (USD Million)
TABLE Europe Osteogenesis Imperfecta Treatment market, by End use, 2016-2027 (USD Million)
TABLE Asia Pacific Osteogenesis Imperfecta Treatment market, by Country, 2016-2027 (USD Million)
TABLE Asia Pacific Osteogenesis Imperfecta Treatment market, by Drugs, 2016-2027 (USD Million)
TABLE Asia Pacific Osteogenesis Imperfecta Treatment market, by treatment type, 2016-2027 (USD Million)
TABLE Asia Pacific Osteogenesis Imperfecta Treatment market, by route of administration, 2016-2027 (USD Million)
TABLE Asia Pacific Osteogenesis Imperfecta Treatment market, by End use, 2016-2027 (USD Million)
TABLE Latin America Osteogenesis Imperfecta Treatment market, by Country, 2016-2027 (USD Million)
TABLE Latin America Osteogenesis Imperfecta Treatment market, by Drugs, 2016-2027 (USD Million)
TABLE Latin America Osteogenesis Imperfecta Treatment market, by treatment type, 2016-2027 (USD Million)
TABLE Latin America Osteogenesis Imperfecta Treatment market, by route of administration, 2016-2027 (USD Million)
TABLE Latin America Osteogenesis Imperfecta Treatment market, by End use, 2016-2027 (USD Million)
TABLE Middle East and Africa Osteogenesis Imperfecta Treatment market, by Country, 2016-2027 (USD Million)
TABLE Middle East and Africa Osteogenesis Imperfecta Treatment market, by Drugs, 2016-2027 (USD Million)
TABLE Middle East and Africa Osteogenesis Imperfecta Treatment market, by treatment type, 2016-2027 (USD Million)
TABLE Middle East and Africa Osteogenesis Imperfecta Treatment market, by route of administration, 2016-2027 (USD Million)
TABLE Middle East and Africa Osteogenesis Imperfecta Treatment market, by End use, 2016-2027 (USD Million)
List of Figures
FIGURE Osteogenesis Imperfecta Treatment market segmentation
FIGURE Market research methodology
FIGURE Value chain analysis
FIGURE Porter’s Five Forces Analysis
FIGURE Market Attractiveness Analysis
FIGURE COVID-19 Impact Analysis
FIGURE Pre & Post COVID-19 Impact Comparision Study
FIGURE Competitive Landscape; Key company market share analysis, 2019
FIGURE Drugs segment market share analysis, 2020 & 2027
FIGURE Drugs segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Teriparatide market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Denosumab market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Other drugs market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Treatment type segment market share analysis, 2020 & 2027
FIGURE Treatment type segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Treatment type market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Medication market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Surgery Monitoring segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Physical Therapy market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Other types market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Routes of administration segment market share analysis, 2020 & 2027
FIGURE Routes of administration segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Routes of administration market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Oral market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Intravenous segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Subcutaneous market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Others market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE End use segment market share analysis, 2020 & 2027
FIGURE End use segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE End use market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Hospital market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Homecare Monitoring segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Specialty clinics market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Other end use market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Regional segment market share analysis, 2020 & 2027
FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE North America Osteogenesis Imperfecta Treatment market share and leading players, 2019
FIGURE Europe Osteogenesis Imperfecta Treatment market share and leading players, 2019
FIGURE Asia Pacific Osteogenesis Imperfecta Treatment market share and leading players, 2019
FIGURE Latin America Osteogenesis Imperfecta Treatment market share and leading players, 2019
FIGURE Middle East and Africa Osteogenesis Imperfecta Treatment market share and leading players, 2019
FIGURE North America market share analysis by country, 2019
FIGURE U.S. Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Canada Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Europe Osteogenesis Imperfecta Treatment market share analysis by country, 2019
FIGURE Germany Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Spain Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Italy Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE UK Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE France Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of the Europe Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Asia Pacific Osteogenesis Imperfecta Treatment market share analysis by country, 2019
FIGURE India Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE China Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Japan Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE South Korea Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Singapore Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of APAC Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Latin America Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Latin America Osteogenesis Imperfecta Treatment market share analysis by country, 2019
FIGURE Brazil Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Mexico Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Argentina Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Rest of LATAM Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Middle East and Africa Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Middle East and Africa Osteogenesis Imperfecta Treatment market share analysis by country, 2019
FIGURE Saudi Arabia Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE United Arab Emirates Osteogenesis Imperfecta Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
